1. Introduction {#sec1}
===============

Although gastric cancer (GC) is the fifth most common cancer, it is the third leading cause of cancer-related mortality worldwide \[[@B1]\]. Through surgery, systemic treatments, and growing stress on multidisciplinary evaluation and treatment of patients, the 5-year net survival rate of GC is generally in the range of 25--30%. However, the median overall survival (OS) of patients with unresectable GC is only 9--11 months with combination cytotoxic chemotherapy as the global standard of care \[[@B2]\]. The human epidermal growth factor receptor (HER)-2 status can be used to predict the effect of targeted therapy and the prognosis. Although the median OS of patients with HER-2-positive GC is extended to 14--16 months with addition of trastuzumab in backbone chemotherapy, patients with HER-2 gene amplification or protein overexpression account for only 20% of the overall GC population \[[@B3], [@B4]\]. The Union for International Cancer Control recommends the tumor-node-metastasis (TNM) classification for GC. However, its predictive value remains deficient, particularly for patients with advanced GC, who have lost the chance for radical surgery. Therefore, there is an increasing demand for novel predictors of the chemotherapy response and survival period in patients with unresectable GC, which will aid physicians by facilitating decision-making in identifying appropriate patients for chemotherapy programs.

The therapeutic effect and prognosis of patients with cancer may be related to their inflammatory and nutritional status. Proinflammatory chemokines and cytokines participate in the occurrence, development, recurrence, and metastasis of tumors, and reduce the effectiveness of cytotoxic drugs, ultimately affecting the prognosis \[[@B5], [@B6]\]. Additionally, patients with cancer are prone to malnutrition, which reduces their tolerance of cancer treatment and the likelihood of response, and is an independent predictor of poor outcome \[[@B7]\]. Among the inflammation- and nutrition-related biomarkers, relevant research has proven that the albumin-to-globulin ratio (AGR), fibrinogen-to-albumin ratio (FAR), neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) have a significant prognostic value in patients with cancer receiving cytotoxic drug therapy \[[@B8]--[@B12]\].

Albumin and globulin alone can develop into indicators of the patients\' prognosis. However, albumin and globulin test results are affected by various factors, including physiological and pathological changes. Studies have combined albumin and globulin as predictors to minimize the impact of the inaccuracy of an isolated value on the result. Numerous studies have reported a relationship between the pretreatment AGR and the treatment response in patients with GC \[[@B13]--[@B15]\]. Compared with albumin, prealbumin has a shorter half-life and a lower plasma concentration \[[@B16]\]. Even minor changes in the nutritional status can be detected by the prealbumin level, which may make prealbumin a potential prognostic factor superior to albumin \[[@B17]\]. In a recent study, it was found that the prealbumin-to-globulin ratio (PGR) can indicate the chemotherapy efficacy and the prognosis of patients with cancer \[[@B18]\]. However, the analysis of the PGR performed in patients with GC was relatively limited.

The main objective of this study was to evaluate whether the pretreatment PGR could develop into a marker of chemotherapy response and a prognostic marker for the progression-free survival (PFS) and OS in patients with unresectable GC receiving first-line chemotherapy. We also compared the PGR with the AGR to determine which is a better prognostic indicator. Thus, this study investigated two potential prognostic factors, the PGR and AGR.

2. Materials and Methods {#sec2}
========================

2.1. Patient Selection and Follow-Up {#sec2.1}
------------------------------------

We retrospectively reviewed the records of patients with nonresectable GC evaluated from January 2013 to January 2018 at the Cancer Hospital of the China Medical University in Shenyang City, Liaoning Province, China.

The following were the enrollment criteria: (1) chemotherapy-naive, stage III-IV unresectable gastric adenocarcinoma diagnosed by biopsy and imaging; (2) an Eastern Cooperative Oncology Group (ECOG) performance status score of 0--2; (3) no severe complications that may hinder patients from receiving chemotherapy; (4) completed at least two cycles of chemotherapy; and (5) completed all required blood tests within 1 week before the initial first-line chemotherapy. We excluded patients with kidney or liver diseases other than tumors and those with severe chronic or acute inflammatory diseases.

Radiographic assessments were performed at baseline and every 6--8 weeks until disease progression. After the failure of first-line chemotherapy, the patients were followed up every 8--12 weeks until they died. Variations of approximately 1 week were regarded as a permissible error.

All enrolled patients volunteered to participate in the study, which was approved by the Ethics Committee of the Cancer Hospital of China Medical University.

2.2. Clinical Data Collection {#sec2.2}
-----------------------------

We collected the following data from the hospital records: the patients\' characteristics before first-line chemotherapy, the location of the tumor in the stomach as determined by gastroscopy, and computed tomography (CT)-, magnetic resonance imaging (MRI)-, and positron emission tomography (PET)/CT-determined metastatic lymph nodes and organs. Peripheral blood analysis and albumin, prealbumin, globulin, hemoglobin, carcinoembryonic antigen (CEA), carbohydrate antigen 72-4 (CA72-4), and carbohydrate antigen 19-9 (CA19-9) levels were obtained within 1 week of treatment initiation. The reference ranges for plasma albumin, prealbumin, globulin, and hemoglobin were 35--50 g/L, 160--450 mg/L, 20--35 g/L, and 115--155 g/L, respectively. The accepted normal ranges of CEA, CA72-4, and CA19-9 were 0--5 ng/ml, 0--6 U/ml, and 0--37 U/ml, respectively. The PGR and AGR were defined as prealbumin (mg/L)/globulin (g/L) ratio and albumin (g/L)/globulin (g/L) ratio, respectively.

All patients received different systemic first-line chemotherapy regimens depending on their ECOG score. Patients were evaluated for therapy response after every two cycles of chemotherapy. We adopted the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) to assess the patients\' chemotherapy response, as follows: complete remission (CR), partial response (PR), stable disease (SD), and disease progression. The objective response rate (ORR) was calculated as CR + PR. The disease control rate (DCR) was calculated as CR + PR + SD. The PFS was defined as the period from first-line chemotherapy until disease progression or death as a result of any cause, whichever occurred first, and the OS was defined as the period from the date of first-line chemotherapy to the date of death from any cause.

2.3. Data Analysis Methods {#sec2.3}
--------------------------

The Statistical Package for Social Sciences version 25 software (SPSS Inc., Chicago, IL, USA) was used for data analysis. We used the cut-off values of the PGR and AGR determined by a receiver operating characteristic curve analysis to divide all patients with unresectable GC into high-value and low-value groups for each factor. Fisher\'s exact test and the chi-square test were used to evaluate the relationship between the PGR or AGR and the patients\' characteristics and therapeutic response. Kaplan-Meier\'s method was used to plot the PFS and OS curves, and the PFS and OS were analyzed using the log-rank test. Pearson\'s correlation analysis was employed to assess the linear correlation between the prognostic factors and the PFS and OS. Univariate and multivariate analyses were performed using a Cox proportional hazards model to identify potential predictors of mortality. We verified that the proportional hazards assumption was met \[[@B19]\]. In the proportional hazards assumption, we classified patients into two groups based on the following criteria: (1) median age of 60 years; (2) body mass index less than 18.5 or greater than 25 kg/m^2^, CEA \>5 ng/mL, CA72-4 \>6 U/mL, CA19-9 \>37 U/mL, and hemoglobin \<115 g/L; abnormal values that may be associated with a poor patient prognosis; and (3) compared with those with ECOG scores 0--1, papillary or tubular adenocarcinoma, TNM stage III, number of tumor organ metastases 0--1, and no peritoneal metastasis, patients with ECOG ≥2, poorly cohesive or mucinous adenocarcinoma, TNM stage IV, number of tumor organ metastases ≥2, and peritoneal metastasis may have a worse prognosis. Those variables that were clinically and statistically significant in the univariate analysis were included in multivariate Cox regression models. A *p* value \<0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Identification of the Optimal Cut-off Value for the PGR and AGR {#sec3.1}
--------------------------------------------------------------------

The median PFS of 151 days was the state variable, the PGR and AGR were used as the test variables, and then, the cut-off values of the above two prognostic components were determined. We found that a PGR of 7.205 and an AGR of 1.455 were the strongest prognostic factors for the PFS. The area under the curve (AUC) values for the PGR and AGR were 0.660 (95% confidence interval \[CI\]: 0.597--0.723, sensitivity = 0.624, specificity = 0.614, *p* \< 0.001) and 0.707 (95% CI: 0.646--0.769, sensitivity = 0.752, specificity = 0.664, *p* \< 0.001), respectively. From the results, the AUC value of the AGR was slightly larger than that of the PGR; thus, the AGR may be better than the PGR for predicting the prognosis of patients. In this study, we set the cut-off values for the PGR and AGR to 7.21 and 1.46, respectively. Patients with a PGR ≥7.21 and an AGR ≥1.46 were categorized in the high-PGR and high-AGR groups, respectively; otherwise, they were categorized in the low-PGR and low-AGR groups, respectively ([Figure 1](#fig1){ref-type="fig"}).

3.2. Clinicopathological Features {#sec3.2}
---------------------------------

A total of 281 patients with advanced GC receiving first-line chemotherapy were included in the analysis. The majority of patients were men (66.55%), and the median age of the patients was 60 years. Among all, 74.38% and 82.92% of patients had a normal body mass index and an ECOG score less than 2 points, respectively. Patients with poorly cohesive or mucinous adenocarcinoma (74.02%) and stage IV disease (80.43%) represented the highest proportions among all patients. The number of patients with more than one organ metastases was the same as that with peritoneal metastases, accounting for 32.38% of the total. SOX (oxaliplatin + S1)/CapeOX (oxaliplatin + capecitabine), FOLFOX (oxaliplatin + leucovorin +5-fluorouracil), and DCF (docetaxel + cisplatin +5-fluorouracil)/DOF (docetaxel + oxaliplatin +5-fluorouracil) were the primary chemotherapy regimens for patients receiving first-line chemotherapy, accounting for 50.53%, 17.44%, and 10.68% of the total, respectively. Based on the RECIST1.1 criteria, the ORR and DCR were 13.17% and 86.12%, respectively. [Table 1](#tab1){ref-type="table"} details the characteristics of the patients.

There were some differences in terms of the histopathological and clinical parameters between the low and high groups. The analysis indicated that a low PGR (*p* = 0.006) and a low AGR (*p* = 0.001) were significantly related to a hemoglobin level \<115 g/L. The probability of more than one organ metastases and peritoneal metastases was statistically higher in the low-AGR group (*p* = 0.029; [Table 2](#tab2){ref-type="table"}).

3.3. Relationship between the PGR and AGR and the First-Line Chemotherapy Response {#sec3.3}
----------------------------------------------------------------------------------

We evaluated the relationship between the PGR and AGR levels before receiving first-line chemotherapy and the treatment response. Patients in the high-PGR (93.66% vs. 78.42%, *p* \< 0.001) and high-AGR (94.12% vs. 76.56%, *p* \< 0.001) groups had a higher DCR than that of those in the low-groups. The high-AGR group had an ORR nearly two times higher than that of the low-AGR group (16.99% vs. 8.59%, *p* = 0.038). Although patients in the high-PGR group tended to have a higher ORR, the difference did not reach statistical significance (15.49% vs. 10.79%, *p* = 0.244). These findings indicate that the AGR may be superior to the PGR in predicting chemotherapy response ([Table 3](#tab3){ref-type="table"}).

3.4. Survival Analysis according to the Pretreatment PGR and AGR {#sec3.4}
----------------------------------------------------------------

Figures [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"} show the Kaplan-Meier curves for survival. The validity of the proportional hazards assumption for the model was assessed via log(−log\[survival\]) plots. In the whole group, the patients\' median PFS and OS were 151 and 322 days, respectively. The high-PGR group had longer median PFS (189 vs. 125 days, *p* \< 0.001) and median OS (350 vs. 288 days, *p* \< 0.001) than those of the low-PGR group. Compared with the low-AGR group, the high-AGR group had extended median PFS (206 vs. 112 days, *p* \< 0.001) and median OS (359 vs. 269 days, *p* \< 0.001).

Pearson\'s correlation analysis indicated that the PGR and AGR values were positively correlated with the PFS and OS in patients with GC (all *p* \< 0.001; [Figure 4](#fig4){ref-type="fig"}).

3.5. Prognostic Factors Influencing the Long-Term Survival {#sec3.5}
----------------------------------------------------------

The univariate and multivariate analyses estimated the factors affecting the PFS and OS (Tables [4](#tab4){ref-type="table"} and [5](#tab5){ref-type="table"}). The univariate Cox regression analyses revealed that the high-PGR group had longer PFS (hazard ratio \[HR\]: 0.644; 95% CI: 0.508--0.817; *p* \< 0.001) and OS (HR: 0.644; 95% CI: 0.507--0.817; *p* \< 0.001) compared with the low-PGR group. Analogous results were found in the high-AGR group. After adjusting for the effects of the prognostic factors in the multivariate analysis, the high-PGR group was still strongly associated with prolonged PFS (HR: 0.672; 95% CI: 0.527--0.857; *p* = 0.001) and OS (HR: 0.675; 95% CI: 0.530--0.861; *p* = 0.002), as was the high-AGR group. Regarding the other prognostic elements in the multivariate analysis, poorly cohesive or mucinous adenocarcinoma, more than one organ affected by metastasis, and CA72-4 \>6 U/mL were associated with limited PFS, and poorly cohesive or mucinous adenocarcinoma, peritoneal dissemination, CEA \>5 ng/mL were associated with unfavorable OS (all *p* \< 0.05).

4. Discussion {#sec4}
=============

Systemic inflammation and malnutrition are prevailing in patients with cancer. These factors have a significant impact on the patients\' quality of life, treatment outcomes, diagnosis, and durability, and may increase the risk of longer duration of hospitalization, infection, treatment toxicity, and treatment costs \[[@B5], [@B7], [@B20], [@B21]\]. These effects are also manifested in patients with GC, particularly those with advanced cancer. Patients with gastrointestinal tumors are more likely to suffer from gastrointestinal obstruction and malabsorption and other complications. Hence, early detection of inflammation and malnutrition is crucial. However, medical workers tend to belittle this fact during anticancer treatment, making it imperative to appraise the inflammatory and nutritional status of patients with cancer.

Multiple studies have investigated a series of inflammatory and nutritional markers available to doctors, including the PGR, AGR, FAR, PLR, NLR, and LMR, for the prognosis of patients with different types of cancer \[[@B18], [@B22]--[@B26]\]. Among them, the AGR, FAR, PLR, NLR, and LMR were frequently applied to anticipate complications and the prognosis of patients with GC \[[@B27]--[@B31]\]. However, there is scant evidence on the relationship between the PGR and the prognosis of patients with GC.

In this study, we explored the prognostic and predictive role of the PGR in patients with GC receiving first-line chemotherapy. First, we found that a low pretreatment PGR was strongly associated with a hemoglobin level of \<115 g/L. A previous study has shown that patients with GC who have anemia have a poor prognosis \[[@B32]\], which indirectly reveals that the PGR is a reliable prognostic biomarker. Next, we assessed the ability of the PGR level to predict the chemotherapy response. Patients in the high-PGR group had a higher DCR than that of those in the low-PGR groups. The high PGR value contributed to a superior ORR, but it did not achieve statistical significance. This was probably due to the small sample size. Furthermore, we found that a high PGR was significantly associated with prolonged OS and PFS in the survival analysis, and the PGR value was positively linearly correlated with the PFS and OS. Finally, the multivariate analysis revealed that the PGR was an independent prognostic indicator for the survival of patients with GC receiving chemotherapy, which further establishes a sturdy bedrock for the PGR to mature into an applicable prognostic biomarker for patients with GC. The inherent mechanisms of the PGR as a prognostic marker for patients with GC are as follows.

First, inflammatory cytokines released by inflammatory cells can cultivate an inflammatory microenvironment, which provides a hotbed for tumor growth. Therefore, chronic inflammation is a contributor to tumor cell growth, angiogenesis, development, progression, recurrence, and metastasis \[[@B5]\]. The level of globulin contained in the PGR may reflect the level of inflammation in patients \[[@B33]\]. As a chronic inflammation biochemical marker, the concentration of serum globulin gradually increases when stimulated by proinflammatory cytokines, such as tumor necrosis factor-*α*, interleukin-6, and interleukin-1b \[[@B34]\]. Previous studies have shown that globulin levels are associated with shorter survival in patients \[[@B35], [@B36]\].

Second, malnutrition relates intimately to a decline in the quality of life, reducing the adherence to treatment and response to therapy. As malnutrition is one of the leading causes for immunodeficiency, the nutritional status can be used to comparatively quickly assess the host\'s immune status \[[@B37], [@B38]\]. Protein-related malnutrition is universal in patients with advanced tumors receiving treatment and eventually leads to the collapse of the cellular and humoral immunity, which is known to play a central role in the defenses against malignant tumor cells. Malnutrition can affect the synthesis of prealbumin, one of the PGR components; thus, prealbumin can be used as a surrogate marker to mirror the nutritional status of patients \[[@B39]\]. Compared with albumin, prealbumin has a shorter half-life of 2 days and a smaller concentration in the body, which makes it susceptible to changes in the serum and an ideal candidate sensitive marker for predicting the prognosis of patients \[[@B40]\]. Earlier studies have discussed the independent prognostic role of serum prealbumin \[[@B41], [@B42]\].

Finally, globulin and prealbumin are two potentially valued elements related to the prognosis of patients with cancer. However, these parameters alone are not sufficient to predict the patients\' prognosis. The globulin level is an inversely related prognostic index, while the prealbumin level is a positively related prognostic index. Integrating indicators into the PGR has improved accuracy. By calculating the ratio of globulin to prealbumin, lower values are accompanied by inflammation or/and malnutrition, which may be related to a poor prognosis. On the contrary, a higher value indicates no inflammation or/and great nutritional status, which can be associated with a favorable prognosis. Therefore, compared with globulin and prealbumin alone, the PGR probably has a better ability to distinguish patients with favorable prognosis from those with unfavorable prognosis.

This study has several strengths. We demonstrated for the first time that the PGR is a significant indicator that can independently predict the PFS and OS in patients with GC receiving first-line chemotherapy. This study was the first to use the PGR as a forecasting element of chemotherapeutic response for patients with GC.

There are also limitations to this study. First, the PGR was found not to be superior to the AGR as a prognostic indicator in this study. This might be because patients with advanced GC have gone through protracted disease history, prolonging chronic malnutrition and inflammation in these patients. Therefore, we speculate that the PGR with a shorter half-life of 2--3 days is superior to the AGR with a half-life of 21 days as a prognostic marker in early-stage patients, but further research is needed to validate this hypothesis. Second, the present was a single-center retrospective study. Hence, the usefulness of the PGR still needs to be verified by multicenter large-scale prospective studies.

5. Conclusions {#sec5}
==============

The prechemotherapy PGR level can predict the chemotherapy effect in patients with advanced GC and is an independent predictor of the PFS and OS. It may be a reliable prognostic tool for medical practitioners.
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###### 

Baseline characteristics of the patients.

  Characteristics                           Cases (*n* = 281)   Percentage
  ----------------------------------------- ------------------- ------------
  Sex                                                           
   Male                                     187                 66.55%
   Female                                   94                  33.45%
  Age (yr)                                                      
   ≤60                                      159                 56.58%
   \>60                                     122                 43.42%
  Body mass index (kg/m^2^)                                     
   \<18.5 or \>25                           72                  25.62%
   18.5--25                                 209                 74.38%
  ECOG                                                          
   0--1                                     233                 82.92%
   ≥2                                       48                  17.08%
  Histological type                                             
   Papillary, tubular,                      73                  25.98%
   Poorly cohesive, mucinous                208                 74.02%
  TNM stage                                                     
   III                                      55                  19.57%
   IV                                       226                 80.43%
  Number of organs affected by metastasis                       
   0--1                                     190                 67.62%
   ≥2                                       91                  32.38%
  Peritoneal metastasis                                         
   Yes                                      91                  32.38%
   No                                       190                 67.62%
  First-line chemotherapy regimen                               
   SOX/CapeOX                               142                 50.53%
   FOLFOX                                   49                  17.44%
   DCF/DOF                                  30                  10.68%
   Capecitabine/S-1                         22                  7.83%
   Others                                   38                  13.52%
  Best response                                                 
   Complete remission                       0                   ---
   Partial response                         37                  13.17%
   Stable disease                           205                 72.95%
   Progression of disease                   39                  13.88%
   Objective response rate                  37                  13.17%
   Disease control rate                     242                 86.12%
  Tumor biomarkers                                              
   CEA \>5 ng/mL                            121                 43.06%
   CA72-4 \>6 U/mL                          158                 56.23%
   CA19-9 \>37 U/mL                         106                 37.72%
  Hemoglobin (g/L)                                              
   \<115                                    105                 37.37%
   ≥115                                     176                 62.63%
  Albumin (g/L)                                                 
   \<35                                     52                  18.51%
   ≥35                                      229                 81.49%
  Prealbumin (mg/L)                                             
   \<160                                    83                  29.54%
   ≥160                                     198                 70.46%
  Globulin (g/L)                                                
   ≤35                                      259                 92.17%
   \>35                                     22                  7.83%
  PGR                                                           
   \<7.21                                   139                 49.47%
    ≥7.21                                   142                 50.53%
  AGR                                                           
   \<1.46                                   128                 45.55%
   ≥1.46                                    153                 54.45%

ECOG: Eastern Cooperative Oncology Group; TNM: tumor-node-metastasis; SOX: oxaliplatin + S1; CapeOX: oxaliplatin + capecitabine; FOLFOX: oxaliplatin + leucovorin + 5-fluorouracil; DCF: docetaxel + cisplatin + 5-fluorouracil; DOF: docetaxel + oxaliplatin + 5-fluorouracil; CEA: carcinoembryonic antigen; CA72-4: carbonhydrate antigen 72-4; CA 19-9: carbonhydrate antigen 19-9; PGR: prealbumin-to-globulin ratio; AGR: albumin-to-globulin ratio.

###### 

Relationship between the pretreatment PGR and AGR and clinicopathological factors.

                                            PGR   AGR                       
  ----------------------------------------- ----- ----- ------- ----- ----- -------
  Sex                                                                       
   Male                                     95    92    0.528   86    101   0.835
   Female                                   44    50    42      52          
  Age (yr)                                                                  
   \>60                                     63    59    0.523   61    61    0.190
   ≤60                                      76    83    67      92          
  Body mass index (kg/m^2^)                                                 
   \<18.5 or \>25                           40    32    0.231   30    42    0.443
   18.5--25                                 99    110   98      111         
  ECOG                                                                      
   0--1                                     113   120   0.474   104   129   0.497
   ≥2                                       26    22    24      24          
  Histological type                                                         
   Papillary, tubular                       35    38    0.763   27    46    0.088
   Poorly cohesive, mucinous                104   104   101     107         
  TNM stage                                                                 
   III                                      26    29    0.717   21    34    0.221
   IV                                       113   113   107     119         
  Number of organs affected by metastasis                                   
   0--1                                     90    100   0.309   78    112   0.029
   ≥2                                       49    42    50      41          
  Peritoneal metastasis                                                     
   Yes                                      52    39    0.075   50    41    0.029
   No                                       87    103   78      112         
  CEA (ng/mL)                                                               
   \>5                                      67    54    0.085   56    65    0.831
   ≤5                                       72    88    72      88          
  CA72-4 (U/mL)                                                             
   \>6                                      79    79    0.839   76    82    0.331
   ≤6                                       60    63    52      71          
  CA19-9 (U/mL)                                                             
   \>37                                     59    47    0.106   52    54    0.359
   ≤37                                      80    95            76    99    
  Hemoglobin (g/L)                                                          
   \<115                                    63    42    0.006   61    44    0.001
   ≥115                                     76    100   67      109         

PGR: prealbumin-to-globulin ratio; AGR: albumin-to-globulin ratio; ECOG: Eastern Cooperative Oncology Group; TNM: tumor-node-metastasis; CEA: carcinoembryonic antigen; CA72-4: carbonhydrate antigen 72-4; CA 19-9: carbohydrate antigen 19-9.

###### 

Treatment response to first-line chemotherapy according to the pretreatment PGR and AGR.

  Response                  PGR      AGR                                  
  ------------------------- -------- -------- --------- -------- -------- ---------
  Complete response         0        0                  0        0        
  Partial response          22       15                 26       11       
  Stable disease            111      94                 118      87       
  Progressive disease       9        30                 9        30       
  Objective response rate   15.49%   10.79%   0.244     16.99%   8.59%    0.038
  Disease control rate      93.66%   78.42%   \<0.001   94.12%   76.56%   \<0.001

PGR: prealbumin to globulin ratio; AGR: albumin to globulin ratio.

###### 

Correlations between survival and the PGR and other clinicopathological factors.

                                                  Progression-free survival   Overall survival                                                                                                 
  ----------------------------------------------- --------------------------- ------------------ --------- ------- ------------- ------- ------- ------------- --------- ------- ------------- -------
  Sex (male)                                      1.073                       0.835-1.379        0.582                                   1.145   0.891-1.471   0.290                           
  Age (\>60 years)                                0.991                       0.781-1.256        0.939                                   0.797   0.627-1.012   0.062     0.874   0.674-1.133   0.309
  Body mass index (\<18.5 or \>25 kg/m^2^)        0.923                       0.705-1.207        0.558                                   1.084   0.828-1.420   0.557                           
  ECOG (≥2)                                       1.124                       0.823-1.535        0.463                                   1.174   0.859-1.604   0.313                           
  Histological type (poorly cohesive, mucinous)   1.492                       1.136-1.959        0.004     1.495   1.137-1.965   0.004   1.537   1.172-2.015   0.002     1.407   1.067-1.855   0.015
  TNM stage (IV)                                  1.206                       0.897-1.622        0.214                                   1.368   1.017-1.839   0.038     1.186   0.855-1.643   0.306
  Number of organs affected by metastasis (≥2)    1.390                       1.081-1.786        0.010     1.400   1.077-1.818   0.012   1.364   1.058-1.758   0.017     1.294   0.973-1.721   0.077
  Peritoneal metastasis (yes)                     1.526                       1.185-1.966        \<0.001   1.297   0.991-1.696   0.058   1.710   1.325-2.205   \<0.001   1.426   1.062-1.915   0.018
  CEA (\>5 ng/mL)                                 1.222                       0.959-1.557        0.105     1.138   0.878-1.474   0.328   1.278   1.004-1.626   0.046     1.299   1.004-1.680   0.046
  CA72-4 (\>6 U/mL)                               1.425                       1.118-1.816        0.004     1.411   1.091-1.824   0.009   1.254   0.989-1.590   0.061     1.164   0.903-1.501   0.240
  CA19-9 (\>37 U/mL)                              1.051                       0.825-1.339        0.686                                   1.046   0.821-1.332   0.717                           
  Hemoglobin (\<115 g/L)                          0.905                       0.708-1.157        0.424                                   0.890   0.697-1.136   0.349                           
  PGR ≥7.21                                       0.644                       0.508-0.817        \<0.001   0.672   0.527-0.857   0.001   0.644   0.507-0.817   \<0.001   0.675   0.530-0.861   0.002

ECOG: Eastern Cooperative Oncology Group; TNM: tumor-node-metastasis; CEA: carcinoembryonic antigen; CA72-4: carbonhydrate antigen 72-4; CA 19-9: carbohydrate antigen 19-9; PGR: prealbumin-to-globulin ratio.

###### 

Correlations between survival and AGR and other clinicopathological factors.

                                                  Progression-free survival   Overall survival                                                                                                   
  ----------------------------------------------- --------------------------- ------------------ --------- ------- ------------- --------- ------- ------------- --------- ------- ------------- ---------
  Sex (male)                                      1.073                       0.835-1.379        0.582                                     1.145   0.891-1.471   0.290                           
  Age (\>60 years)                                0.991                       0.781-1.256        0.939                                     0.797   0.627-1.012   0.062     0.877   0.678-1.135   0.320
  Body mass index (\<18.5 or \>25 kg/m^2^)        0.923                       0.705-1.207        0.558                                     1.084   0.828-1.420   0.557                           
  ECOG (≥2)                                       1.124                       0.823-1.535        0.463                                     1.174   0.859-1.604   0.313                           
  Histological type (poorly cohesive, mucinous)   1.492                       1.136-1.959        0.004     1.355   1.028-1.787   0.031     1.537   1.172-2.015   0.002     1.352   1.023-1.787   0.034
  TNM stage (IV)                                  1.206                       0.897-1.622        0.214                                     1.368   1.017-1.839   0.038     1.182   0.852-1.640   0.318
  Number of organs affected by metastasis (≥2)    1.390                       1.081-1.786        0.010     1.341   1.030-1.746   0.029     1.364   1.058-1.758   0.017     1.299   0.977-1.728   0.072
  Peritoneal metastasis (yes)                     1.526                       1.185-1.966        \<0.001   1.239   0.947-1.621   0.118     1.710   1.325-2.205   \<0.001   1.419   1.056-1.907   0.020
  CEA (\>5 ng/mL)                                 1.222                       0.959-1.557        0.105     1.146   0.883-1.487   0.305     1.278   1.004-1.626   0.046     1.381   1.066-1.787   0.014
  CA72-4 (\>6 U/mL)                               1.425                       1.118-1.816        0.004     1.418   1.093-1.840   0.009     1.254   0.989-1.590   0.061     1.150   0.891-1.485   0.284
  CA19-9 (\>37 U/mL)                              1.051                       0.825-1.339        0.686                                     1.046   0.821-1.332   0.717                           
  Hemoglobin (\<115 g/L)                          0.905                       0.708-1.157        0.424                                     0.890   0.697-1.136   0.349                           
  AGR ≥1.46                                       0.419                       0.328-0.535        \<0.001   0.454   0.353-0.583   \<0.001   0.584   0.460-0.742   \<0.001   0.602   0.472-0.769   \<0.001

ECOG: Eastern Cooperative Oncology Group; TNM: tumor-node-metastasis; CEA: carcinoembryonic antigen; CA72-4: carbonhydrate antigen 72-4; CA 19-9: carbohydrate antigen 19-9; AGR: albumin-to-globulin ratio.

[^1]: Academic Editor: Alvaro González
